Spooner C E, Markowitz N P, Saravolatz L D
Division of Infectious Diseases and Hospital Epidemiology, Henry Ford Hospital, Detroit, Michigan 48202.
Clin Immunol Immunopathol. 1992 Jan;62(1 Pt 2):S11-7. doi: 10.1016/0090-1229(92)90036-n.
There is an increasing incidence of sepsis among hospitalized patients. Also, high mortality associated with sepsis and septic shock persists despite appropriate antibiotic therapy. Recent investigations have demonstrated that bacterial antigens stimulate a cascade of cellular mediators or cytokine release. In sepsis and septic shock the response of these cytokines often exceeds natural downregulation and leads to multisystem organ failure and even death in an unacceptably high number of patients. Many investigative studies have shown that tumor necrosis factor (TNF) is the prime mediator of the inflammatory response seen in sepsis and septic shock. Sepsis management in the future will include immune modulating therapy directed against the deleterious effects of cytokines, specifically TNF. This article reviews the current problem of sepsis and the evidence to support the role of TNF in sepsis. also, recent studies employing monoclonal antibodies against TNF as well as considerations for future studies are discussed.
住院患者中脓毒症的发病率正在上升。此外,尽管进行了适当的抗生素治疗,但与脓毒症和脓毒性休克相关的高死亡率仍然存在。最近的研究表明,细菌抗原会刺激一系列细胞介质或细胞因子的释放。在脓毒症和脓毒性休克中,这些细胞因子的反应常常超过自然下调,导致多系统器官衰竭,甚至在大量患者中导致不可接受的高死亡率。许多调查研究表明,肿瘤坏死因子(TNF)是脓毒症和脓毒性休克中炎症反应的主要介质。未来的脓毒症治疗将包括针对细胞因子,特别是TNF的有害作用的免疫调节治疗。本文综述了当前脓毒症问题以及支持TNF在脓毒症中作用的证据。此外,还讨论了最近使用抗TNF单克隆抗体的研究以及对未来研究的考虑。